newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147